

## **Disclosure of Transfers of Value Methodology Note for Tetris Pharma 2022**

### Tetris Pharma methodology, 2022

Tetris Pharma began trading in July 2021 and is a specialty pharmaceutical business focused on taking branded medicines to market as well as developing and acquiring niche injectable and topical products. During 2022 one branded and five generic products were marketed by Tetris Pharma solely in the UK. No research and educational grants and donations were made. Tetris Pharma had no active product development programmes in 2022. All payments during the chronological year 2022 were reviewed. The total spending was reviewed with finance functions. The aggregated total is declared on the accompanying spread sheet.

In collating disclosure data, the following methodologies have been used:

- Amounts declared included VAT applied.
- Amounts declared are in UK sterling.
- There were no other payments worldwide.
- Contracts were for a single year of 2022.
- Tetris Pharma does not have any over-the-counter business or medical device business.
- Individual consent has been sought for individual payments to healthcare professionals with no refusals.
- Tetris Pharma has made no non-monetary transfers of value in 2022
- Tetris Pharma has no joint working to disclose in 2022
- Tetris Pharma made three Unrestricted Educational Grants to patient groups and no Donations to patient groups in 2022.